Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| BMGF | Other Grant/Funding Number | BMGF |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to determine the strategy for mass drug administration (MDA) which provides the greatest reductions in prevalence and intensity of Schistosoma mansoni in school-aged children after 4 years of intervention.
Intestinal schistosomiasis is caused by the blood-dwelling flatworm Schistosoma mansoni. Despite the increasing focus on the use of praziquantel against schistosomiasis infections for the last three decades many areas in Sub-Saharan Africa still have high prevalences and intensities of schistosomiasis especially among school-age children. This is true for the area of Mwanza Region of Tanzania adjacent to Lake Victoria. The study is a six arm study and includes 150 communities (25 in each arm). From each community 100 school children (aged 9-12 years), 100 first year students (aged 7-8 years) and 50 adults (aged 20-55 years) are included, diagnosed and treated with praziquantel using strategies composing of a mixture of community wide treatment (CWT), school-based treatment (SBT) and years without treatment (-T). The 100 school children provided stool specimens on three consecutive days, while the 100 first year students and 50 adults with few exceptions only provided one specimen. The treatment strategies during the 4 years for the different arms are as follows: Arm 1: CWT, CWT, CWT, CWT; Arm 2: CWT, CWT, SBT, SBT; Arm 3: CWT, CWT -T, -T; Arm 4: SBT, SBT, SBT, SBT; Arm 5: SBT, SBT, -T, -T; Arm 6: SBT, -T, SBT, -T.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MDA once a year | Experimental | Community wide treatment (CWT) once a year for four years with single dose praziquantel 40mg/kg |
|
| MDA 2nd year CWT follwed by 2 years SBT | Experimental | Treatment with praziquantel as arm 1 given by two years of community wide treatment (CWT) followed by two years of school-based treatment (SBT) |
|
| Praziquantel every second year CWT | Experimental | Treatment with praziquantel given every second year as CWT |
|
| MDA once a year SBT | Experimental | Treatment with praziquantel as above given as 4 years of SBT |
|
| MDA given for 2 years as SBT | Experimental | Treatment with praziquantel as above given for 2 years as SBT followed by 2 years without MDA |
|
| MDA as SBT 1year and 1 year without MDA |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Praziquantel | Drug | Six different treatment strategies with praziquantel |
|
| Measure | Description | Time Frame |
|---|---|---|
| Effect of Mass drug administration on prevalence and intensity of Schistosoma mansoni among children and adults | Prevalence and intensity of Schistosoma mansoni | May -October 2016 (5 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Mass drug administration coverage | Coverage of treatment | May -October 2016 (5 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Cost of different treatment arm | Cost of different treatment arm | May-October 2016 (5 months) |
Inclusion Criteria:
-All school children and adults who consent to participate can be included
Exclusion Criteria:
-Those not consenting or with any chronic disease not related to schistosomiasis will be excluded
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Safari Kinung'hi, PhD | National Institute for Medical Research, Mwanza Research Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institute for Mediacal Research | Mwanza | Kagera | Tanzania |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012552 | Schistosomiasis |
| ID | Term |
|---|---|
| D014201 | Trematode Infections |
| D006373 | Helminthiasis |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D011223 | Praziquantel |
| ID | Term |
|---|---|
| D007546 | Isoquinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Treatment with praziquantel given as one years of SBT alternating with one year without treatment |
|
|
| D000079426 |
| Vector Borne Diseases |